141 related articles for article (PubMed ID: 37167784)
1. A nanotherapeutic strategy that engages cytotoxic and immunosuppressive activities for the treatment of cancer recurrence following organ transplantation.
Yang Z; Xie H; Wan J; Wang Y; Zhang L; Zhou K; Tang H; Zhao W; Wang H; Song P; Zheng S
EBioMedicine; 2023 Jun; 92():104594. PubMed ID: 37167784
[TBL] [Abstract][Full Text] [Related]
2. Chemically engineered mTOR-nanoparticle blockers enhance antitumour efficacy.
Tang H; Dilimulati D; Yang Z; Zhou K; Chen X; Sun R; Wang N; Liang Z; Bian S; Zhao J; Song P; Zheng S; Wang H; Xie H
EBioMedicine; 2024 Apr; 103():105099. PubMed ID: 38604089
[TBL] [Abstract][Full Text] [Related]
3. A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma.
Schnitzbauer AA; Zuelke C; Graeb C; Rochon J; Bilbao I; Burra P; de Jong KP; Duvoux C; Kneteman NM; Adam R; Bechstein WO; Becker T; Beckebaum S; Chazouillères O; Cillo U; Colledan M; Fändrich F; Gugenheim J; Hauss JP; Heise M; Hidalgo E; Jamieson N; Königsrainer A; Lamby PE; Lerut JP; Mäkisalo H; Margreiter R; Mazzaferro V; Mutzbauer I; Otto G; Pageaux GP; Pinna AD; Pirenne J; Rizell M; Rossi G; Rostaing L; Roy A; Turrion VS; Schmidt J; Troisi RI; van Hoek B; Valente U; Wolf P; Wolters H; Mirza DF; Scholz T; Steininger R; Soderdahl G; Strasser SI; Jauch KW; Neuhaus P; Schlitt HJ; Geissler EK
BMC Cancer; 2010 May; 10():190. PubMed ID: 20459775
[TBL] [Abstract][Full Text] [Related]
4. Conversion to sirolimus immunosuppression in liver transplantation recipients with hepatocellular carcinoma: Report of an initial experience.
Zhou J; Fan J; Wang Z; Wu ZQ; Qiu SJ; Huang XW; Yu Y; Sun J; Xiao YS; He YF; Wang YQ; Tang ZY
World J Gastroenterol; 2006 May; 12(19):3114-8. PubMed ID: 16718799
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of sorafenib in combination with mammalian target of rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation.
Gomez-Martin C; Bustamante J; Castroagudin JF; Salcedo M; Garralda E; Testillano M; Herrero I; Matilla A; Sangro B
Liver Transpl; 2012 Jan; 18(1):45-52. PubMed ID: 21932373
[TBL] [Abstract][Full Text] [Related]
6. Radiologic complete response with sirolimus and sorafenib in a hepatocellular carcinoma patient who relapsed after orthotopic liver transplantation.
Kim R; Aucejo F
J Gastrointest Cancer; 2011 Mar; 42(1):50-3. PubMed ID: 20714941
[TBL] [Abstract][Full Text] [Related]
7. Metronomic capecitabine with rapamycin exerts an immunosuppressive effect by inducing ferroptosis of CD4
Wang H; Yang R; Wang Z; Cao L; Kong D; Sun Q; Yoshida S; Ren J; Chen T; Duan J; Lu J; Shen Z; Zheng H
Int Immunopharmacol; 2023 Nov; 124(Pt A):110810. PubMed ID: 37625370
[TBL] [Abstract][Full Text] [Related]
8. Examinations of Factors Influencing Survival of Liver Transplantation for Hepatocellular Carcinoma: A Single-Center Experience From Budapest.
Piros L; Fehérvári I; Görög D; Nemes B; Szabó J; Gerlei Z; Végső G; Kóbori L; Máthé Z
Transplant Proc; 2015 Sep; 47(7):2201-6. PubMed ID: 26361680
[TBL] [Abstract][Full Text] [Related]
9. Sirolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma.
Zimmerman MA; Trotter JF; Wachs M; Bak T; Campsen J; Skibba A; Kam I
Liver Transpl; 2008 May; 14(5):633-8. PubMed ID: 18324656
[TBL] [Abstract][Full Text] [Related]
10. Sirolimus and metformin synergistically inhibit hepatocellular carcinoma cell proliferation and improve long-term survival in patients with HCC related to hepatitis B virus induced cirrhosis after liver transplantation.
Shen C; Peng C; Shen B; Zhu Z; Xu N; Li T; Xie J
Oncotarget; 2016 Sep; 7(38):62647-62656. PubMed ID: 27577068
[TBL] [Abstract][Full Text] [Related]
11. Hepatocellular carcinoma and liver transplantation: clinical perspective on molecular targeted strategies.
Matsuda Y; Ichida T; Fukumoto M
Med Mol Morphol; 2011 Sep; 44(3):117-24. PubMed ID: 21922382
[TBL] [Abstract][Full Text] [Related]
12. [A retrospective cohort study regarding the effect of sirolimus-based immunosuppression protocol on the long-term survival of hepatocellular carcinoma patients after liver transplantation].
Zhao X; Lu S; Wang M; Wu J; Lin D; Guo Q; Lai W; Zeng D; Li C; Liu Y; Sun L; Yan D; Li N
Zhonghua Wai Ke Za Zhi; 2014 Apr; 52(4):245-8. PubMed ID: 24924566
[TBL] [Abstract][Full Text] [Related]
13. The impact of mTOR inhibitors on the development of malignancy.
Geissler EK
Transplant Proc; 2008 Dec; 40(10 Suppl):S32-5. PubMed ID: 19100904
[TBL] [Abstract][Full Text] [Related]
14. Everolimus-based immunosuppression in patients with hepatocellular carcinoma at high risk of recurrence after liver transplantation: a case series.
Ferreiro AO; Vazquez-Millán MA; López FS; Gutiérrez MG; Diaz SP; Patiño MJ
Transplant Proc; 2014 Dec; 46(10):3496-501. PubMed ID: 25498079
[TBL] [Abstract][Full Text] [Related]
15. Systematic review with meta-analysis: sirolimus- or everolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma.
Grigg SE; Sarri GL; Gow PJ; Yeomans ND
Aliment Pharmacol Ther; 2019 May; 49(10):1260-1273. PubMed ID: 30989721
[TBL] [Abstract][Full Text] [Related]
16. Mammalian target of rapamycin inhibitors are associated with lower rates of hepatocellular carcinoma recurrence after liver transplantation: a systematic review.
Cholongitas E; Mamou C; Rodríguez-Castro KI; Burra P
Transpl Int; 2014 Oct; 27(10):1039-49. PubMed ID: 24943720
[TBL] [Abstract][Full Text] [Related]
17. A mixed blessing for liver transplantation patients - Rapamycin.
Fan GH; Zhang CZ; Gao FQ; Wei XY; Ling SB; Wang K; Wang JG; Zheng SS; Nikfarjam M; Xu X
Hepatobiliary Pancreat Dis Int; 2023 Feb; 22(1):14-21. PubMed ID: 36328894
[TBL] [Abstract][Full Text] [Related]
18. Sirolimus and liver transplantation: clinical implications for hepatocellular carcinoma.
Campsen J; Zimmerman MA; Trotter JF; Wachs M; Bak T; Mandell S; Kam I
Expert Opin Pharmacother; 2007 Jun; 8(9):1275-82. PubMed ID: 17563262
[TBL] [Abstract][Full Text] [Related]
19. Clinical analysis of patients with hepatocellular carcinoma recurrence after living-donor liver transplantation.
Na GH; Hong TH; You YK; Kim DG
World J Gastroenterol; 2016 Jul; 22(25):5790-9. PubMed ID: 27433092
[TBL] [Abstract][Full Text] [Related]
20. Antitumor effect of sorafenib and mammalian target of rapamycin inhibitor in liver transplantation recipients with hepatocellular carcinoma recurrence.
Jung DH; Tak E; Hwang S; Song GW; Ahn CS; Kim KH; Moon DB; Ha TY; Park GC; Ryoo BY; Lee KJ; Kim N; Kwon JH; Jwa EK; Lee SG
Liver Transpl; 2018 Jul; 24(7):932-945. PubMed ID: 29710388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]